# An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma

> **NCT00552396** · PHASE1 · COMPLETED · sponsor: **Innate Pharma** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Anti-KIR (1-7F9)

## Key facts

- **NCT ID:** NCT00552396
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552396, "An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00552396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*